Table 2.
Clinical and demographic characteristics in patients with US assessment.
| Case | Age | Sex | Cancer | Treatment | Prednisone Dose (mg/d) | Clinical Pattern | Pre-Rheum | T from CPI and irAEs (Months) | Previous irAEs |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 78 | M | Melanoma | Pembrolizumab | - | PMR-like | - | 1 | Colitis |
| 2 | 74 | M | Urinary tract | Nivolumab + Ipilumab | - | RA-like | - | 1 | - |
| 3 | 78 | M | Prostate | Nivolumab | 10 | RA-like | - | 12 | - |
| 4 | 75 | F | Melanoma | Nivolumab | 60 | RA-like | - | 2 | - |
| 5 | 72 | M | Lung | Nivolumab | 40 | RA-like | - | 2 | - |
| 6 | 77 | M | Vesical | Pembrolizumab | 5 | PMR-like | - | 2 | - |
| 7 | 60 | M | Melanoma | Nivolumab | - | PMR-like | Seronegative arthrtitis | 6 | - |
| 8 | 73 | M | Prostate | Atezolizumab | 20 | PMR-like | - | 1 | - |
| 9 | 76 | M | Hepatocarcinoma | Atezolizumab | - | PMR-like | - | 1 | - |
| 10 | 53 | F | Melanoma | Pembrolizumab | - | PsA-like | - | 31 | - |
| 11 | 68 | F | Melanoma | Pembrolizumab | 7,5 | Oligoarthritis | Fibromyalgia | 11 | - |
| 12 | 58 | M | Hepatocarcinoma | Durvalumab | 10 | Oligoarthritis | - | 20 | Peripheral polyneuropathy |
| 13 | 74 | M | Lung | Atezolizumab | - | Monoarthritis | Chondrocalcinosis | 5 | - |
| 14 | 72 | M | Leukemia | Anti-TIM3 | - | Monoarthritis | Uveitis HLA-B27+ | 9 | - |
| 15 | 59 | M | Hepatocarcinoma | Nivolumab | - | PsA-Like (Dactylitis) | - | 7 | - |
Pre-Rheum: previous rheumatic diseases. T. from CPI and irAEs: time from checkpoint inhibitor and immune-related adverse events: Anti-TIM3: Anti T cell immunoglobulin mucin domain 3, PMR-Like: Polymyalgia rheumatica like, RA-like: Rheumatoid Arthritis like, PsA-like: Psoriatic arthritis-like.